N-[2-(1H-indol-3-yl)ethyl]-4-(4-quinolin-1-ium-1-ylbutoxy)benzamide;bromide | 1415036-65-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-[2-(1H-indol-3-yl)ethyl]-4-(4-quinolin-1-ium-1-ylbutoxy)benzamide;bromide
• CAS: 1415036-65-5
• 化学式: Br*C₃₀H₃₀N₃O₂
• 分子量: 544.491
• InChiKey: MUZOWAJCKRWDDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.44
• 重原子数：
  36
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  58
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  对羟基苯甲酸 在 potassium carbonate 、 N,N'-二环己基碳二亚胺 、 potassium iodide 作用下， 以 四氢呋喃 、 丙酮 、 乙腈 、 Petroleum ether 为溶剂， 反应 121.0h， 生成 N-[2-(1H-indol-3-yl)ethyl]-4-(4-quinolin-1-ium-1-ylbutoxy)benzamide;bromide
  参考文献：
  名称：

  Design, synthesis, and bioevaluation of benzamides: Novel acetylcholinesterase inhibitors with multi-functions on butylcholinesterase, Aβ aggregation, and β-secretase

  摘要：

  Alzheimer's disease (AD) is a multifactorial syndrome with several target proteins contributing to its etiology. In this study, we conducted a structure-based design and successfully produced a series of new multi-site AChE inhibitors with a novel framework. Compound 2e, characterized by a central benzamide moiety linked to an isoquinoline at one side and acetophenone at the other, was the most potent candidate with K-i of 6.47 nM against human AChE. Particularly, it showed simultaneous inhibitory effects against BChE, A beta aggregation, and beta-secretase. We therefore conclude that compound 2e is a very promising multi-function lead for the treatment of AD. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.09.016

文献信息

• Design, synthesis, and bioevaluation of benzamides: Novel acetylcholinesterase inhibitors with multi-functions on butylcholinesterase, Aβ aggregation, and β-secretase
  作者：Da-Yong Peng、Qi Sun、Xiao-Lei Zhu、Hong-Yan Lin、Qiong Chen、Ning-Xi Yu、Wen-Chao Yang、Guang-Fu Yang

  DOI：10.1016/j.bmc.2012.09.016

  日期：2012.11

  Alzheimer's disease (AD) is a multifactorial syndrome with several target proteins contributing to its etiology. In this study, we conducted a structure-based design and successfully produced a series of new multi-site AChE inhibitors with a novel framework. Compound 2e, characterized by a central benzamide moiety linked to an isoquinoline at one side and acetophenone at the other, was the most potent candidate with K-i of 6.47 nM against human AChE. Particularly, it showed simultaneous inhibitory effects against BChE, A beta aggregation, and beta-secretase. We therefore conclude that compound 2e is a very promising multi-function lead for the treatment of AD. (C) 2012 Elsevier Ltd. All rights reserved.